Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 460

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 460
---
 audit committee of a listed company may not, other
than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (i) accept,
directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries;
or (ii) be an affiliated person of the listed company or any of its subsidiaries.

Our
executive officers are elected by, and serve at the discretion of, our board of directors.

Board
Meetings and Attendance

During
the 2024 fiscal year, the board of directors held five (5) board meetings, with all board members in attendance for each, and
also conducted other matters by unanimous written consent.

Annual
Meeting Attendance

On
October 22, 2024, the Company held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). Set forth below
are the five proposals that were voted on at the Annual Meeting and the stockholder votes on each such proposal, as certified
by the inspector of elections for the Annual Meeting. These proposals are described in further detail in the Definitive Proxy
Statement on Schedule 14A filed by the Company with the SEC on September 26, 2024 (the “Proxy Statement”).

As
of the close of business on September 20, 2024, the record date for the Annual Meeting, 5,766,704 shares of the Company’s
common stock, par value $0.0001 per share (“Common Stock”), were issued, outstanding and entitled to vote. Holders
of shares of Common Stock were entitled to one vote per share for each share of Common Stock. Stockholders holding an aggregate
of 3,950,312 votes were present at the Annual Meeting, in person or represented by proxy, which number constituted a quorum.

85 

Proposal
1 – The five (5) nominees named in the Proxy Statement were elected at the Annual Meeting to serve as the Company’s
directors until the Company’s 2025 Annual Meeting of Stockholders and until each of their respective successors are elected
and qualified or until each of their earlier resignation or removal. The final voting results with respect to the election of
each such nominee were as follows:

    Nominee
     
    For
     
    Withheld

    Todd Davis
     
    3,534,258
     
    815

    Ezra Friedberg